topotecan has been researched along with Bone Cancer in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P | 1 |
| Agaoglu, FY; Cakir, FB; Darendeliler, E; Gorgun, O; Kebudi, R | 1 |
| Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB | 1 |
| Bohr, VA; Christmann, M; Gestrich, C; Kaina, B; Roos, WP; Tomicic, MT | 1 |
| Cassier, P; Chapet, O; Chekrine, T; De Bari, B; Kulisa, M; Mornex, F | 1 |
| Deméocq, F; Halle, P; Isfan, F; Kanold, J; Kelly, A; Lang, P; Marabelle, A; Merlin, E; Paillard, C; Rochette, E; Tchirkov, A | 1 |
| Abboud, M; Eid, T; El-Solh, H; Farhat, R; Feghaly, J; Khoury, NJ; Muwakkit, S; Raad, R; Saab, R | 1 |
| Beriwal, S; Garcia-Young, JA; Singh, S | 1 |
| Davidson, NE; Gradishar, WJ; Kennedy, MJ; Lord, RS; O'Neill, A; Stewart, JA; Wolff, AC; Wood, WC | 1 |
| Bernstein, ML; Devidas, M; Dickman, PS; Dubowy, R; Gebhardt, M; Goorin, A; Grier, HE; Lafreniere, D; Link, MP; Meyers, PA; Nicholas, R; Perlman, EJ; Souid, AK; Stine, K; Wainer, IW | 1 |
| Hunold, A; Jürgens, H; Liebscher, C; Paulussen, M; Ranft, A; Weddeling, N | 1 |
| Dethling, J; Fink, T; Hans, K; Koschel, G; Lorenz, R; Mueller, C; Schade-Brittinger, C; Schroeder, H; Seifart, U; Wolf, M | 1 |
| Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A | 1 |
| Breitfeld, PP; Chen, Z; Drachtman, R; Greffe, B; Healey, J; Krailo, M; Meyers, PA; Nachman, J; Nadel, H; Reaman, GH; Sato, JK; Seibel, NL | 1 |
| DeClerck, YA; Groshen, SG; Moats, RA; Nelson, MD; Peng, H; Reynolds, CP; Sohara, Y; Ye, W | 1 |
| Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Bleyer, WA; Gillespie, A; Krailo, MD; Needle, MN; Poplack, DG; Reaman, GH; Sato, JK | 1 |
| Bernstein, ML; Harris, MB; Hayashi, R; Kepner, JL; Saylors, RL; Stine, KC; Sullivan, J; Vietti , TJ; Wall, DA | 1 |
1 review(s) available for topotecan and Bone Cancer
| Article | Year |
|---|---|
[Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature].
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma in Situ; Carcinoma, Neuroendocrine; Carcinoma, Transitional Cell; Combined Modality Therapy; Emergencies; Etoposide; Humans; Lymphatic Irradiation; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Prognosis; Prostatic Hyperplasia; Topoisomerase I Inhibitors; Topotecan; Urinary Bladder Neoplasms | 2011 |
7 trial(s) available for topotecan and Bone Cancer
| Article | Year |
|---|---|
Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193.
Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Breast Neoplasms; DNA Topoisomerases, Type I; Doxorubicin; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Middle Aged; Soft Tissue Neoplasms; Topotecan | 2005 |
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Amifostine; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Sarcoma, Ewing; Topotecan | 2006 |
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Sarcoma, Ewing; Survival Rate; Topotecan; Treatment Outcome | 2006 |
Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Small Cell; Central Nervous System Neoplasms; Cisplatin; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Time Factors; Topotecan; Treatment Outcome | 2007 |
Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Female; Humans; Lung Neoplasms; Maximum Tolerated Dose; Osteosarcoma; Prognosis; Survival Analysis; Survival Rate; Topotecan | 2007 |
Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Soft Tissue Neoplasms; Topotecan | 1998 |
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infant; Infusions, Intravenous; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma, Ewing; Topotecan | 2001 |
9 other study(ies) available for topotecan and Bone Cancer
| Article | Year |
|---|---|
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan | 2004 |
A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Sarcoma, Ewing; Topotecan; Vincristine | 2013 |
Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Pilot Projects; Sarcoma, Ewing; Soft Tissue Neoplasms; Topotecan; Vincristine | 2016 |
WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Bone Neoplasms; Bromodeoxyuridine; Cell Cycle; Cell Survival; Colony-Forming Units Assay; DNA Breaks; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Exodeoxyribonucleases; Histones; Humans; Osteosarcoma; RecQ Helicases; RNA, Small Interfering; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Werner Syndrome Helicase | 2008 |
NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Neoplasms; Bone Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Doublecortin Domain Proteins; Haplotypes; Hematopoietic Stem Cell Transplantation; Homeodomain Proteins; Humans; Immunotherapy; Interleukin-2; Killer Cells, Natural; Male; Microtubule-Associated Proteins; Neoplasm, Residual; Neuroblastoma; Neuropeptides; Remission Induction; Temozolomide; Topotecan; Transcription Factors; Transplantation, Homologous; Tyrosine 3-Monooxygenase | 2012 |
Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Male; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Sarcoma, Ewing; Topotecan; Treatment Outcome; Young Adult | 2013 |
Tumor lysis syndrome in extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Small Cell; Enzyme Inhibitors; Fatal Outcome; Female; Humans; Lung Neoplasms; Topotecan; Tumor Lysis Syndrome | 2002 |
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine | 2007 |
The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Caspase 3; Cell Growth Processes; Cell Survival; Cyclophosphamide; Diphosphonates; Enzyme Activation; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neuroblastoma; Osteoclasts; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; ras Proteins; Topotecan; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |